Evidence map›Paper›PMID 41791790›Full record

ArticleJournal for immunotherapy of cancer2026

Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas.

Matilde Monti, Sara Picinoli, Anna Bozzola, Marco Ferrari, Mattia Bugatti, Irene Pezzali, Marco Carlomagno, Giada Carta, Matteo Orlandi, Giacomo Lora and 20 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Matilde MontiMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Sara PicinoliMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Anna BozzolaUnit of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy.
Marco FerrariDepartment of Neuroscience, University of Padua, Padua, Italy.
Mattia BugattiMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Irene PezzaliMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Marco CarlomagnoDepartment of Biotechnology, University of Verona, Verona, Italy.
Giada CartaDepartment of Biotechnology, University of Verona, Verona, Italy.
Matteo OrlandiDepartment of Biotechnology, University of Verona, Verona, Italy.
Giacomo LoraDepartment of Biotechnology, University of Verona, Verona, Italy.
Luisa Benerini GattaDepartment of Transfusion Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Francesco MissaleDepartment of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Giorgia FerrariMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Valentina BaldazziMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Sara RezzolaMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Giovanna TabelliniMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Silvia ParoliniMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Marcello ManfrediDepartment of Translational Medicine, University of Eastern Piedmont Amedeo Avogadro School of Medicine, Novara, Italy.
Veronica De GiorgisDepartment of Translational Medicine, University of Eastern Piedmont Amedeo Avogadro School of Medicine, Novara, Italy.
Emilio MarengoDepartment of Sciences and Technological Innovation, University of Eastern Piedmont Amedeo Avogadro - Alessandria Campus, Alessandria, Italy.
Mario Turri-ZanoniUnit of Otorhinolaryngology and Head and Neck Surgery, University of Insubria Department of Biotechnology and Life Sciences, Varese, Italy.
Piero NicolaiDepartment of Neuroscience, University of Padua, Padua, Italy.
Francesca ConsoliUnit of Oncology, ASST Spedali Civili di Brescia, Brescia, Italy.
Davide LombardiDepartment of Medical and Surgical Specialties, Università degli Studi di Brescia, Brescia, Italy.
Paolo MartiniMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.
Jinglun LiMedicine, Washington University School of Medicine in Saint Louis, St. Louis, Missouri, USA.
Obi GriffithWashington University in St Louis School of Medicine, St Louis, Missouri, USA.
Malachi GriffithWashington University in St Louis School of Medicine, St Louis, Missouri, USA.
Marzia RossatoDepartment of Biotechnology, University of Verona, Verona, Italy.
William VermiMolecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy william.vermi@unibs.it.ORCID http://orcid.org/0000-0002-2291-2997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucosal melanomas (MM) arise from mucosal melanocytes at various anatomical sites. These tumors are rare, highly aggressive, and often associated with poor outcomes. Current treatments, including immune checkpoint inhibitors, show limited efficacy in advanced disease. Compared with cutaneous melanomas, there is a lack of data on the immunogenicity and interferon (IFN)-γ sensitivity of MM. In this study, we examined these features in sino-nasal melanomas (SN-MM) cell lines and clinical samples using microscopy and functional genomics.

methodsThe immune contexture of SN-MM was analyzed by immunohistochemistry on 48 tumor biopsies. RNA sequencing and mass spectrometry-based proteomic approaches were used to study the IFN-γ receptor (IFNGR) pathways in five patient-derived SN-MM cell lines. Moreover, their IFN-γ sensitivity, in terms of cell viability, IFNGR/JAK/STAT signaling pathway and IFN-γ inducible proteins, was evaluated by flow cytometry and immunoblots. Neoantigen prediction was performed through integrated whole exome sequencing and RNA-sequencing analysis using pVAC-Seq. Immune effector functions were evaluated in co-culture in vitro assays.

resultsSN-MM tumors are mainly immune "desert" with few tumor-infiltrating lymphocytes and contain immunosuppressive macrophages, features linked to poor prognosis; moreover, tumor cells are largely CD274/programmed death-ligand 1 negative. SN-MM cell lines express transcripts for melanocytic and cancer testis antigens; moreover, sequencing analysis identified a repertoire of high-confidence neoantigens, including candidates derived from recurrently mutated oncogenic drivers. Functional assays revealed that SN-MM cells are susceptible to NK cell-mediated killing. In terms of IFN-γ sensitivity, SN-MM cells show normal surface expression of IFNGR and maintain the integrity of the IFNGR/JAK/STAT signaling pathway. Transcriptomic and proteomic analyses demonstrate that SN-MM cell lines, as a group, respond to IFN-γ by upregulating genes involved in immune recognition and antigen presentation. In 60% of SN-MM lines, IFN-γ also induces cytotoxic and anti-proliferative effects, the release of CXCL10 and upregulation of CD274/PD-L1. The remaining SN-MM cell lines, characterized by poor differentiation, show refractoriness to these effects.

conclusionsSN-MM displays an immune-desert phenotype yet retains intrinsic immunogenicity. Most tumors preserve functional IFN-γ signaling, while poorly differentiated cells show resistance to IFN-γ-mediated effects. These findings underscore heterogeneity in immune responsiveness and support functional immune profiling to refine immunotherapy strategies in MM.

Indexed as

ImmunotherapyMelanomaReceptors, InterferonCell Line, TumorFemaleHumansInterferon-gammaInterferon gamma ReceptorMaleSignal TransductionInterferon-gammaInterferon gamma ReceptorReceptors, InterferonHead and Neck CancerImmune Checkpoint InhibitorImmunotherapyTumor Microenvironment

Identifiers

PMID41791790
PMCPMC12970127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.